Kelly, who made several key hires at the CDRH and helped negotiate the last user fee agreement, announced his departure in a ...

Unveiling of the new factory comes as Merck and other pharma companies face pressure to reshore manufacturing back to the U.S.

The biotech will commit $150 million to an alliance that hands it significant production capacity for a closely watched ...

Trial results show vepdegestrant, a protein-degrading drug Arvinas is developing with Pfizer, improved on fulvestrant in a ...

The deal ends 2Seventy’s short run as an independent company, during which it restructured, sold off research and lost nearly ...

While initial study results suggest Beam's technology can correct alpha-1 antitrypsin deficiency's genetic roots, shares fell ...

A study in people with obesity and diabetes again found CagriSema helps people lose weight, but not by enough to clearly ...

Findings from a pair of studies in tough-to-treat hypertension establish Mineralys’ drug as a “derisked, almost-commercial ...

Development strategies designed to reduce the unknowns so that cell and gene therapy innovators can develop robust processes ...

The president’s deregulatory agenda will mean more responsibility rests on healthcare stakeholders to get artificial ...

Biopharma companies require optimal clone yields to ensure maximum concentration and effectiveness of these therapeutic ...

The struggling retail pharmacy chain entered an agreement to be purchased by private equity firm Sycamore Partners, which ...